Wuhan Hvsen Biotechnology Co Ltd (300871) - Total Liabilities

Latest as of March 2026: CN¥980.24 Million CNY ≈ $143.44 Million USD

Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has total liabilities worth CN¥980.24 Million CNY (≈ $143.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Wuhan Hvsen Biotechnology Co Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300871 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Wuhan Hvsen Biotechnology Co Ltd Competitors by Total Liabilities

The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Udemy Inc NASDAQ:UDMY	USA	$407.24 Million
People & Technology Inc KQ:137400	Korea	₩1.14 Trillion
Lotte Chilsung Beverage KO:005300	Korea	₩2.66 Trillion
Aeroflex Industries Limited NSE:AEROFLEX	India	Rs1.09 Billion
Shanghai Jiaoda Onlly Co Ltd SHG:600530	China	CN¥362.45 Million
Ledman Optoelectronic Co Ltd SHE:300162	China	CN¥713.97 Million
Gem-Year Industrial Co Ltd SHG:601002	China	CN¥989.67 Million
Newsmax, Inc. NYSE:NMAX	USA	$119.23 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300871 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.93	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.43	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Wuhan Hvsen Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)

The table below shows the annual total liabilities of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥822.17 Million ≈ $120.31 Million	-46.94%
2024-12-31	CN¥1.55 Billion ≈ $226.74 Million	+5.68%
2023-12-31	CN¥1.47 Billion ≈ $214.55 Million	+1.28%
2022-12-31	CN¥1.45 Billion ≈ $211.84 Million	+28.93%
2021-12-31	CN¥1.12 Billion ≈ $164.30 Million	+200.96%
2020-12-31	CN¥373.08 Million ≈ $54.59 Million	+37.26%
2019-12-31	CN¥271.80 Million ≈ $39.77 Million	+91.30%
2018-12-31	CN¥142.08 Million ≈ $20.79 Million	+17.36%
2017-12-31	CN¥121.06 Million ≈ $17.72 Million	+19.67%
2016-12-31	CN¥101.16 Million ≈ $14.80 Million	--

About Wuhan Hvsen Biotechnology Co Ltd

SHE:300871 China Biotechnology

Market Cap

$675.00 Million

CN¥4.61 Billion CNY

Market Cap Rank

#10965 Global

#3092 in China

Share Price

CN¥22.86

Change (1 day)

+0.04%

52-Week Range

CN¥19.24 - CN¥32.62

All Time High

CN¥48.84